Heart Failure Research

Heart failure, also known as congestive heart failure or CHF, is an inability of the heart to pump sufficient blood around the body.Heart failure typically occurs secondary to an existing pathology that alters cardiac function. Examples of syndromes that can precede heart failure include myocardial infarction, arrhythmia or infection. These can also cause dilated cardiomyopathy, a condition which accounts for approximately one third of all cases of heart failure. The pathogenesis of heart failure is cyclical and progressive; endogenous mechanisms, which are activated during heart failure in an attempt to counteract the symptoms, actually worsen cardiac function. Cardiac dysfunction, either systolic or diastolic, triggers a decrease in stroke volume and a resultant increase in cardiac output. In healthy individuals the body responds to decreases in cardiac output by initiating the renin-angiotensin-aldosterone system (RAAS) to promote fluid retention, and also by activating the sympathetic nervous system to cause peripheral vasoconstriction. Under normal circumstances this counteracts the imbalance in stroke volume, restoring cardiac output to normal levels. In patients with heart failure the increase in blood volume, together with the heightened peripheral resistance and elevated levels of circulating catecholamines, causes an increased load on the already weakened ventricles with each contraction, and the stroke volume does not return to normal levels. Repeated cycles of this process further weaken the ventricle walls, prompting ventricular hypertrophy and a decreased force of contraction.

Heart Failure Research Products Targets

Products for Heart Failure Research - Page 6

  1. Cat.No. Product Name Information/Activity
  2. BCC6728 Spiroxatrine 1054-88-2 Spiroxatrine chemical structure
  3. BCN6268 Yohimbine Hydrochloride Yohimbine Hydrochloride is an alpha 2-adrenoreceptor antagonist, blocking the pre- and postsynaptic alpha-2 adrenoreceptors and causing an increased release of noradrenaline and dopamine. Yohimbine Hydrochloride chemical structure
  4. BCC6813 Agmatine sulfate Agmatine sulfate exerts modulatory action at multiple molecular targets, such as neurotransmitter systems, ion channels and nitric oxide synthesis. It is an endogenous agonist at imidazoline receptor and a NO synthase inhibitor. Agmatine sulfate chemical structure
  5. BCC6861 Xamoterol hemifumarate 73210-73-8 Xamoterol hemifumarate chemical structure
  6. BCC6633 (S)-(-)-Atenolol 93379-54-5 (S)-(-)-Atenolol chemical structure
  7. BCC4343 Betaxolol HCl Betaxolol Hydrochloride is a selective beta1 adrenergic receptor blocker used in the treatment of hypertension and glaucoma. Betaxolol HCl chemical structure
  8. BCC4344 Bisoprolol fumarate (±)-Bisoprolol (hemifumarate) is a selective type β1 adrenergic receptor blocker. Bisoprolol fumarate chemical structure
  9. BCC6893 CGP 20712 dihydrochloride 1216905-73-5 CGP 20712 dihydrochloride chemical structure
  10. BCC4330 Metoprolol Tartrate Metoprolol is a cardioselective β1-adrenergic blocking agent. Metoprolol Tartrate chemical structure
  11. BCC4340 Timolol Maleate (S)-Timolol Maleate (L-714,465 Maleate) is a non-cardioselective hydrophilic β-adrenoceptor blocker. (S)-Timolol Maleate is widely used as standard medication for intraocular pressure (glaucoma) by preventing the production of aqueous humor. (S)-Timolol Maleate can be used for hypertension, angina pectoris and myocardial infarction. Timolol Maleate chemical structure

Items 51 to 60 of 148 total